Track topics on Twitter Track topics that are important to you
Phone: 1 312-755-0798
Acorda loses appeal to shield Ampyra from generic entry https://buff.ly/2wYZhqm
We're at @BioCentury 26th NewsMakers conference in NYC. Here's a list (PDF) of the Presenting Companies today: https://www.biocentury.com/sites/default/files/NM18schedule.pdf …https://www.biocentury.com/conferences/newsmakers-2018 …
We're at @BioCentury 26th NewsMakers conference in NYC. Here's a list (PDF) of the Presenting Companies today: https://www.biocentury.com/sites/default/files/NM18schedule.pdf … https:/...
5 yrs after members of its own AdComm advised rethinking the CVOT guidance for diabetes drugs, @US_FDA will have a meeting on Oct. 24-25 to do just that. Original story from 2013
Last week, the #biotech industry raised $1.1B, bringing to $60.9B the total raised YTD. Want to run your own analysis? Chk out our BioCentury BCIQ database: https://bciq.biocentury.com/marketing ...
U.K. patient group @GeneticAll_UK is leading the charge to change how @NICEComms assesses Orphan drugs, with a nudge from Parliament. @StephenPHansen has the story on NICE's problem with
ICER not impressed by first RNAi or @Alnylam performance-based agreement. Says both its and @akceatx hATTR treatments have low value. Via @EMcCallister01 in @BioCentu
.@NIHDirector Collins tells @BioCentury he is "very troubled" by a letter he received from a prominent Chinese scientist expressing indignation over NIH's public warnings about foreign influ...
ICYMI: China big pharma Sihuan launches global BD unit in US led by Frank Leslie Boyd Jr. (former Teva, $GSK) https://www.biocentury.com/bc-extra/company-news/2018-09-05/management-tracks-sihuan-launches-us-unit … via @BioCenturyhttps://twitter.com/Bi
ICYMI: China big pharma Sihuan launches global BD unit in US led by Frank Leslie Boyd Jr. (former Teva, $GSK) https://www.biocentury.com/bc-extra/company-news/2018-09-05/management-tracks-sihuan-la...
BioCentury has pioneered the creation of turf-neutral, independent venues for the corporate and investment communities to conduct business. As a result, these events are known by the quality of their ...
ScarX Therapeutics is a Toronto-based life sciences company founded in partnership with The Hospital for Sick Children and MaRS Innovation, which discovers and develops innovative...
This century is already being coined the ‘Biocentury', as the fruits of fifty years of research in the field of molecular biology begin to affect our world. Medical advances over the next hundred ye...
We have published hundreds of BioCentury news stories on BioPortfolio along with dozens of BioCentury Clinical Trials and PubMed Articles about BioCentury for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioCentury Companies in our database. You can also find out about relevant BioCentury Drugs and Medications on this site too.